NCT03350815 - Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis | Biotech Hunter

Enrollment

322

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

March 11, 2021

Study Completion Date

May 29, 2021

Conditions

Ankylosing Spondylitis

Interventions

DRUG

150 mg open-label secukinumab

All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.

DRUG

150 mg double-blinded secukinumab

Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)

DRUG

300 mg double-blinded secukinumab

Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)

Trial Locations (65)

10016

Novartis Investigative Site, New York

11201

Novartis Investigative Site, Brooklyn

13676

Novartis Investigative Site, Potsdam

14127

Novartis Investigative Site, Orchard Park

15090

Novartis Investigative Site, Wexford

16635

Novartis Investigative Site, Duncansville

20902

Novartis Investigative Site, Wheaton

21740

Novartis Investigative Site, Cumberland

Novartis Investigative Site, Hagerstown

25304

Novartis Investigative Site, Charleston

29204

Novartis Investigative Site, Columbia

29460

Novartis Investigative Site, Charleston

30096

Novartis Investigative Site, Duluth

32608

Novartis Investigative Site, Gainesville

32720

Novartis Investigative Site, DeLand

32810

Novartis Investigative Site, Orlando

33180

Novartis Investigative Site, Aventura

33321

Novartis Investigative Site, Tamarac

33324

Novartis Investigative Site, Plantation

33486

Novartis Investigative Site, Boca Raton

33511

Novartis Investigative Site, Brandon

33542

Novartis Investigative Site, Zephyrhills

33609

Novartis Investigative Site, Tampa

33705

Novartis Investigative Site, St. Petersburg

38119

Novartis Investigative Site, Memphis

38305

Novartis Investigative Site, Jackson

44130

Novartis Investigative Site, Middleburg Heights

45219

Novartis Investigative Site, Cincinnati

45402

Novartis Investigative Site, Dayton

47715

Novartis Investigative Site, Evansville

48081

Novartis Investigative Site, Saint Clair Shores

54220

Novartis Investigative Site, Manitowoc

54650

Novartis Investigative Site, Onalaska

55435

Novartis Investigative Site, Edina

58701

Novartis Investigative Site, Minot

60061

Novartis Investigative Site, Vernon Hills

62703

Novartis Investigative Site, Springfield

65810

Novartis Investigative Site, Springfield

71203

Novartis Investigative Site, Monroe

72401

Novartis Investigative Site, Jonesboro

73103

Novartis Investigative Site, Oklahoma City

75150

Novartis Investigative Site, Mesquite

75231

Novartis Investigative Site, Dallas

76034

Novartis Investigative Site, Colleyville

77025

Novartis Investigative Site, Houston

77089

Novartis Investigative Site, Houston

77701

Novartis Investigative Site, Beaumont

84132

Novartis Investigative Site, Salt Lake City

87102

Novartis Investigative Site, Albuquerque

87505

Novartis Investigative Site, Santa Fe

91786

Novartis Investigative Site, Upland

92260

Novartis Investigative Site, Palm Desert

92354

Novartis Investigative Site, Loma Linda

92780

Novartis Investigative Site, Tustin

92835

Novartis Investigative Site, Fullerton

97239

Novartis Investigative Site, Portland

97330

Novartis Investigative Site, Corvallis

98104

Novartis Investigative Site, Seattle

98195

Novartis Investigative Site, Seattle

99204

Novartis Investigative Site, Spokane

02111

Novartis Investigative Site, Boston

01655

Novartis Investigative Site, Worcester

48109 5271

Novartis Investigative Site, Ann Arbor

07432

Novartis Investigative Site, Midland Park

08043

Novartis Investigative Site, Voorhees Township